抗乙型肝炎病毒药物研究进展  

New Development of Anti-Hepatitis B Virus Drugs

作　　者：张雪[1] 苏慧灵 余海飞 周长林[1] 郭敏 ZHANG Xue;SU Hui-ling;YU Hai-fei;ZHOU Chang-lin;GUO Min(School of Life Science and Technology,China Pharmaceutical University,Nanjing 211198,China)

机构地区：[1]中国药科大学生命科学与技术学院,江苏南京211198

出　　处：《药物生物技术》2021年第5期537-542,共6页Pharmaceutical Biotechnology

基　　金：国家自然科学基金项目(No.81700756)。

摘　　要：乙型肝炎病毒(Hepatitis B Virus)是一种经体液传播的的DNA病毒,可引起急性和慢性肝炎。急性肝炎尚未有有效治疗药物,治疗目的是保持身体舒适和营养平衡。而慢性肝炎主要服用干扰素/核苷类似物等抗病毒治疗药物,以延缓肝硬化或原发性肝癌的发生发展。但这两类药物或疗效有限、副作用明显,或需长期服用,导致病毒耐药,总之都不能彻底治愈乙肝,因此急需新型抗病毒治疗药物的出现或辅助。文章旨在对当前已上市或正在研发中的药物进展进行综述,以便优化抗乙肝病毒治疗方案,推动抗乙肝病毒新药的研发。Hepatitis B virus(HBV)is a kind of DNA virus that can be transmitted through body fluid.It can cause acute and chronic hepatitis.There is no treatment for acute hepatitis.The purpose of treatment is to maintain body comfort and nutritional balance.Chronic hepatitis B infection can be treated with antiviral drugs to delay the transformation of hepatitis B virus to cirrhosis and primary liver cancer,including interferon and nucleoside analogues.However,interferon has limited curative effect and obvious side effects.Nucleoside analogues need to be taken for a long time,which can easily lead to virus resistance.In short,they cannot completely cure hepatitis B.Therefore,the emergence or assistance of new antiviral therapy drugs is urgently needed.This paper aims to review the new progress of the therapeutic drugs that have been listed or are being studied,so as to optimize the anti HBV treatment scheme and promote the research and development of new anti HBV drugs.

关 键 词：乙型肝炎病毒 流行病学调查 抗病毒治疗 生物药物 化学药物 中医药 

分 类 号：R978.7[医药卫生—药品]